## **DECLARATION** FOR PATENT APPLICATION

As a below named inventor(s), I/We hereby declare that:

, 10 a poisti .				
	My/Our residence(s), post office address(es) and citizenship(s) are as stated below my name(s). I/We verily believe I am/we are the original, first and sole/joint inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:			
	Oligonucleotides Inhibant L'Expression De La Proteine OB-RGRP Et Procede De Detection De Compo Modifiant L'Interaction Entre Les Proteines De La Famille De OB-RGRP Et Le Recepteur De La Lep			
	and the specification of w (check one)	was filed on and was amende was described ar	as U.S. Application Number d on (if applicable). d claimed in PCT Int'l Application Number filed on mended under PCT Article 19 on (if any).	
	including the claims as an I/We acknowledge the du	nended by any amendment re	ent and Trademark Office all information known to me/us to	
	I/We hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or 365 (b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one other country other than the United States of America, listed below and having a filing date before that of the application on which priority is claimed. I/We have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:			
	0204542	-	40/5-1	
Foreign Priority:	0301543 Number	France Country	10/February/2003 Day/Month/Year Filed	
		,		
Prior Foreign Appln(s):	Number	Country	Day/Month/Year Filed	
$\boxtimes$	I/We hereby claim the benefit under Title 35, United States Code §119(e) of any United States Provisional application(s) listed below:			
	60/461,005 Number	April 7, 2003 Filing Date		
	I/We hereby claim the benefit under Title 35, United States Code §120 or 365(c) of any United States application(s) or international application designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I/We acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.			
	Application Serial No.	Filing Date	Status (Patented, Pending)	
I/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States code §1001, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.				
Inventors(s):	Additional names	and signatures are attached.		
1. Full name: <u>F</u>	Ralf Jockers	2	Full name: Cyril Couturier	
Signature:		Si	gnature:	
			griature:ate:	
Country of Citiz	zenship: France		ountry of Citizenship: France	
			esidence: Paris, France	
	res Sur Yvette, France (City and State/City and Cour		(City and State/City and Country only)	
P. O. Address:	94 rue de Gometz		O. Address: 17 rue Benard	
	Bures Sur Yvette, Franc	e 91440	Paris, France 75014	

3. Full name: Eugen Uhlmann	- 4. Full name:
Signature:	Signature:
Date:	Date:
Country of Citizenship: Germany	Country of Citizenship:
Residence: Glashuetten, Germany (City and State/City and Country only)	Residence: (City and State/City and Country only)
P. O. Address: Zum Talblick 31	P. O. Address:
Glashuetten, Germany 61479	

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206
P.O. Box 6800
Mail Code D-303A
Bridgewater, NJ 08807-0800
Telephone (908) 231-4797
Telefax (908) 231-2626

Aventis Docket No. FRAV2003/0005 US NP